Celcuity Inc: Clinical Trials

4 trials sponsored by Celcuity Inc, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 recruiting, 1 terminated. 4 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1
Phase 23Active not recruiting 1, Recruiting 1, Terminated 1

Follow Celcuity Inc: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Gedatolisib, Darolutamide - mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male
Phase 1 / Phase 2RecruitingCelcuity Inc542024-01-012026-04-13
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Neratinib, Capmatinib - Metastatic Breast Cancer, Breast Cancer
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center102022-08-182025-06-11
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Gedatolisib, Talazoparib - TNBC - Triple-Negative Breast Cancer
Phase 1 / Phase 2Active not recruitingKari Wisinski372019-04-172024-06-07
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Gedatolisib, Palbociclib, Letrozole - Breast Cancer
Phase 1CompletedCelcuity Inc1412016-06-142022-07-27

Conditions studied

Breast Neoplasms (2)  ·  Genital Diseases, Male (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Male Urogenital Diseases (1)  ·  Prostatic Diseases (1)  ·  Prostatic Neoplasms (1)  ·  Prostatic Neoplasms, Castration-Resistant (1)  ·  Triple Negative Breast Neoplasms (1)

Interventions

gedatolisib (3)  ·  Fulvestrant (1)  ·  Letrozole (1)  ·  capmatinib (1)  ·  darolutamide (1)  ·  neratinib (1)  ·  palbociclib (1)  ·  talazoparib (1)

Countries

United States (4)  ·  France (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Igor Gorbatchevsky, MD (1)  ·  Kari Wisinski, MD (1)  ·  Nadene Zack, MS (1)  ·  Rachel Layman (1)

Results publications

PMID 38547892, PMID 40471518